Overview | Capital Markets | Sullivan & Worcester

Capital Markets

Biotech Focused On Developing Non-Opioid Therapeutics to Alleviate Pain Announced IPO

Sullivan was issuer's counsel for Chromocell Therapeutics Corporation, a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, in their $6.6 million initial public offering of common stock.

The Sullivan team was led by David Danovitch, director of the firm’s Corporate Department, with partners Charles E. Chambers Jr., Aaron Schleicher and associate Brian Hurley. Sullivan has developed a strength in working with entrepreneurial biotech and tech companies in the U.S. and in Israel.

David E. Danovitch, Charles E. Chambers Jr. and Brian P. Hurley

Neural Input Technology Company, Wearable Devices Ltd. IPO

Sullivan represented Wearable Devices Ltd., a growth company developing a non-invasive neural input interface technology in the form of a wrist wearable band for controlling digital devices using subtle finger movements for B2B and B2C customers, in its $16 million initial public offering. Wearable Devices is based in Israel and aims to create a world in which the user’s hand becomes a universal input device for touchlessly interacting with technology, and that their technology is setting the standard input interface for the Metaverse.

Howard E. Berkenblit, Oded Har-Even, Tamilla Nurizada and Ilana Neck Levin

U.S. and foreign businesses rely on Sullivan's Capital Markets group to handle sophisticated financial transactions worldwide. Clients seek our experienced counsel, practical business acumen, international finance connections, and ability to balance legal and business risks.

We excel in the flawless execution required in a range of financing transactions in both equity and debt and in securities law compliance, providing experienced and nuanced counsel in all transaction types, a variety of markets, and in all market conditions. Clients appreciate our responsiveness to their needs, including disclosure, reporting, and enforcement issues. In addition to U.S.-based companies, we have extensive experience representing foreign issuers globally and providing them with securities law and capital markets advice.

Our clients comprise a wide range of publicly traded and privately owned businesses, foreign companies and sources of equity capital and debt financing, such as banks, financial institutions, and individual or institutional investors. Our global capital markets team routinely executes on a full range of financing transactions, including, among others:

Initial public offerings (IPOs)
Follow-on/secondary public offerings
Venture capital investments
Private placements of securities
Convertible/equity-linked offerings
Strategic partnerships
SPACs and de-SPAC transactions
Digital asset and tokenized securities offerings
Spin-offs
ATM and ELOCs
Public M&A-related listings and compliance

We also regularly prepare registration statements for our issuer clients, handle their periodic SEC filings, handle stock exchange listings and overall manage compliance with rules and regulations governing every aspect of the capital markets ecosystem.

Clients

We represent publicly traded and privately owned businesses (including foreign companies who trade or raise capital in the U.S.), broker dealers and investment firms. Supplementing our core capital markets practice, we have capital markets attorneys who enjoy a particular subject matter expertise in the REITs, technology and the biotech sectors. Our capital markets lawyers routinely handle transactions around the globe, including across Israel and the Middle East, Asia and Europe. We routinely advise boards of directors and company officers in securities transactions and corporate governance matters.

We help clients meet the challenges and obligations of complying with a myriad of state and federal rules, including Blue Sky compliance, Sarbanes-Oxley, Dodd-Frank and stock exchange listing standards. We counsel boards of directors and their committees on:

Fiduciary duties
Executive compensation
Company policies and procedures
Insurance
Whistleblower complaints
Bylaw provisions
Clawback policies
Risk management
Auditor independence
Internal control over financial reporting; and
Other compliance issues

With experienced lawyers from multiple, seamlessly connected departments within the firm, we represent management, boards, audit and other committees, as well as individual executives, employees and directors. We also provide corporate governance counseling for mutual funds and their directors through our Investment Management Group.

Representative Client Work

Our recent experience includes two senior debt offerings by REITs and an offering of American Depositary Shares by a manufacturer of 3D printers for electronic circuit boards. Total gross proceeds raised in these offerings are nearly $1.5 billion (on top of the over $10 billion we helped our clients raise in the past three years in the public markets).

Here is a selected sample of recent Capital Markets clients and experience:

Securities

Sales agent counsel in a $6 billion up-sized At-The-Market (ATM) public offering of common stock, and placement agent counsel in a $425 million private placement of common stock, by a global marketing partner to leading sportsbooks and online casino gaming operators
Issuers or underwriters in numerous IPOs in the biotechnology and technology industries
Office, government properties, senior living and hotel REITs in raising tens of billions of dollars in public and 144A offerings of common equity, straight and convertible preferred equity and senior and convertible debt
Ongoing disclosure, governance and listing advice to Iron Mountain Incorporated, including public and 144A equity and debt offerings
Represented FINRA placement agent in registered direct for a Chinese biotechnology company focusing on early cancer screening and detection
Represented REIT as issuer in first initial public offering (IPO)
Facilitated senior subordinated debt placements denominated in British Pounds Sterling (GPB), Canadian dollars (CAD) and Euro (EUR) for a U.S. public company; provided ongoing disclosure, corporate governance and stock exchange listing advice for same public client
Public senior living community operator in a convertible note offering
Lead underwriter in several follow-on public equity offerings by a biotech company
Public companies acquisitions with both registered and unregistered stock consideration
Various companies in self-tender offers for outstanding notes
A private financial services firm in a $700 million 144A debt offering
A foreign software company in an acquisition and a going private transaction involving U.S. software company
A REIT in an acquisition and public spinoff of a travel center company
A biotech company in multiple "registered direct" offerings of common stock and warrants
A medical devices company traded on the Tel Aviv Stock Exchange in its ADR listing on Nasdaq followed by a $47 million public offering
Software and technology companies in equity and convertible note PIPEs
A financial services company in switching its listing from Nasdaq to NYSE
Companies whose shares were quoted on the OTC markets with uplisting to Nasdaq

Corporate Governance

Ensured observance of Sarbanes-Oxley Act requirements and stock exchange listing standards
Advised on financing alternatives under the JOBS Act
Developed compliance charters, policies and procedures for issuer's board of directors/management
Counseled board committees and independent directors
Offered guidance on procedures for and responses to whistleblower allegations
Advised on adoption of executive compensation "clawback" policy
Facilitated development and oversight of executive compensation plans
Developed disclosure and social media policies
Counseled officers and directors on fiduciary duties and state law governance practices

Client Highlights

All Client Highlights

Neural Input Technology Company, Wearable Devices Ltd. IPO

Viewpoints

All Viewpoints

SEC Approves NYSE and NYSE American $0.25 Minimum Trading Price as Continued Listing Requirement

On August 14, 2026, the Securities and Exchange Commission (SEC) approved proposed rule changes by the New York Stock Exchange LLC (NYSE) and NYSE American LLC (NYSE American) to adopt a new continued listing requirement imposing a minimum trading price of $0.25 per share. This approval follows the SEC’s recent approval of Nasdaq’s new $5 million Market Value of Listed Securities continued listing requirement and reflects a broader trend by the national securities exchanges to tighten continued listing standards for very low-priced and low-market-capitalization issuers.1 Effective July 1, 2027, the new rules are expected to have a particularly significant impact on micro-cap, small-cap and development-stage public companies. Beginning on that date, a NYSE or NYSE American listed security that closes below $0.25 per share on any trading day will be subject to immediate trading suspension and delisting. Overview of the New Requirement Under the approved rules, NYSE and NYSE American will be required to take immediate delisting action if a listed security closes below $0.25 per share on any trading day. This represents a significant change from the exchanges’ historical approach to low-price continued listing deficiencies. For NYSE issuers, the rule amends Section 802.01C of the NYSE Listed Company Manual. For NYSE American issuers, the rule amends Section 1003 of the NYSE American Company Guide. If a security closes below $0.25 per share: the applicable exchange will immediately suspend trading; the exchange will commence delisting proceedings; the issuer will not be eligible to submit a compliance plan or receive a cure period for that deficiency; and the issuer may appeal the delisting determination in accordance with the applicable exchange rules. This represents a significant departure from the traditional approach to many continued listing deficiencies, which often provide issuers with a period to regain compliance while remaining listed. SEC’s Rationale for Approval The SEC approved the rules on an accelerated basis after considering comments from market participants and the exchanges’ stated concerns regarding very low-priced securities. The exchanges argued that securities trading at extremely low prices may be more susceptible to volatility and market manipulation and may raise concerns regarding the maintenance of fair and orderly markets. The SEC agreed that the rules are reasonably designed to address investor protection and market integrity concerns. In its analysis, the SEC noted that securities falling below the $0.25 threshold historically showed a significant likelihood of continuing to trade below that level and, in many cases, were later delisted for other quantitative continued listing deficiencies. At the same time, the SEC acknowledged comments raising concerns that an automatic suspension and delisting trigger could affect issuers experiencing temporary market dislocation or short-term trading pressure. The SEC nevertheless concluded that the delayed effective date and the exchanges’ continuing appeal procedures supported approval. Practical Impact for Listed Companies The new minimum trading price requirement creates a material compliance consideration for NYSE and NYSE American issuers, particularly micro-cap, small-cap, development-stage and capital-intensive companies whose securities trade near or below $1.00 per share. Unlike NYSE’s existing $1.00 average closing price requirement and Nasdaq’s existing $1.00 minimum bid price requirement, both of which generally provide issuers with a period to regain compliance, the new NYSE and NYSE American $0.25 threshold provides no cure period before suspension and delisting proceedings are initiated. NYSE or NYSE American listed issuers should also consider the rule together with other exchange requirements and limitations, including rules relating to reverse stock splits, market capitalization, stockholders’ equity, market value of publicly held shares, public float and shareholder approval requirements. For many smaller issuers, addressing minimum trading price concerns may require advance planning and should not be left until the issuer is already approaching the $0.25 threshold. What Public Companies Should Do Now NYSE and NYSE American listed issuers whose securities trade at low prices should evaluate the potential impact of the new rule before the effective date. Companies should consider: monitoring closing trading prices on an ongoing basis, and reviewing exchange compliance holistically, including market capitalization, equity, and public float requirements; assessing whether the company may be at risk of approaching the $0.25 threshold; evaluating timing and corporate approvals for a potential reverse stock split; considering capital raising or strategic alternatives where appropriate; and developing contingency plans in the event the company’s trading price deteriorates, including considering the potential consequences of a trading suspension, delisting and a possible transition to the OTC market. The delayed effective date of July 1, 2027 is intended to provide affected issuers with time to take proactive steps, including by seeking shareholder approval for a reverse stock split where required. Once effective, however, the rule will not provide for a traditional compliance plan or cure period. * * * * * * * * If you would like further information regarding the new listing standards discussed in this Client Alert or related exchange compliance matters, please contact the lawyer at Sullivan & Worcester LLP with whom you regularly consult, or any of the lawyers listed above. This Client Alert is provided for general informational purposes only and does not constitute legal advice. 1 The SEC’s July 22, 2026 approval of Nasdaq’s $5 million Market Value of Listed Securities continued listing requirement is currently stayed pending further Commission review. For additional information, see Sullivan & Worcester LLP, SEC Stays Approval of Nasdaq’s $5 Million MVLS Continued Listing Requirement Pending Commission Review (August 3, 2026).

SEC Stays Approval of Nasdaq’s $5 Million MVLS Continued Listing Requirement Pending Commission Review

On July 29, 2026, the Securities and Exchange Commission (the "SEC") notified Nasdaq that it had received notices of intention to petition for review of the SEC's July 22, 2026 order approving Nasdaq's proposed rule change requiring listed companies to maintain a minimum Market Value of Listed Securities ("MVLS") of $5 million. Pursuant to Rule 431(e) of the SEC's Rules of Practice, the July 22, 2026 approval order has been stayed pending further review. As discussed in our July 23, 2026 client alert, the approved rule established a new continued listing standard applicable to companies listed on the Nasdaq Capital Market, Nasdaq Global Market and Nasdaq Global Select Market. Under the approved rule, issuers that failed to maintain an MVLS of at least $5 million for 30 consecutive business days would become subject to immediate delisting procedures without the benefit of a traditional cure period. The Effect of the Stay The SEC's July 29, 2026 letter does not reverse or vacate the July 22, 2026 approval of the rule. Rather, it temporarily suspends the effectiveness of that order. According to the SEC, the stay will remain in effect "until the Commission orders otherwise." As a result, the implementation of Nasdaq's new $5 million MVLS continued listing requirement is currently on hold. Until the SEC takes further action, market participants should monitor developments regarding the review process and any subsequent order. Practical Considerations for Nasdaq Issuers Despite the stay, Nasdaq-listed companies that may be affected by the proposed MVLS requirement should continue to evaluate their compliance position and consider the potential impact of the rule should it ultimately become effective. In particular, issuers that may be at risk of falling below the proposed $5 million MVLS requirement should closely monitor whether, if the stay is lifted, any period following the July 22, 2026 approval order will count toward the rule's 30 consecutive business day requirement. We will continue to monitor developments and provide updates as additional information becomes available. For More Information If you would like additional information regarding the SEC's stay of Nasdaq's proposed $5 million MVLS continued listing requirement, the ongoing review process, Nasdaq listing standards generally, or the implications of these developments for your company, please contact the Sullivan & Worcester lawyer with whom you regularly work or any of the attorneys listed below. David Danovitch, Partner (New York) | +1 (212) 660-3060 | ddanovitch@sullivanlaw.com Oded Har-Even, Partner (New York and Tel-Aviv) | +1 (212) 660-3063 | ohareven@sullivanlaw.com Howard Berkenblit, Partner (Boston) | +1 (617) 338-2979 | hberkenblit@sullivanlaw.com Angela Gomes, Partner (Boston) | +1 (617) 338-2957 | agomes@sullivanlaw.com Joseph Segilia, Partner (New York) | +1 (212) 660-3027 | jsegilia@sullivanlaw.com Ron Ben-Bassat, Partner (New York) | +1 (212) 660-5003 | rbenbassat@sullivanlaw.com Eric Victorson, Partner (New York) | +1 (212) 660-3092 | evictorson@sullivanlaw.com Brendan O'Brien, Partner (New York) | +1 (212) 660-3013 | bobrien@sullivanlaw.com Phillip Carnevale, Associate (New York) | +1 (212) 660-3002 | pcarnevale@sullivanlaw.com Elizabeth Johnson, Associate (New York) | +1 (212) 660-3006 | ejohnson@sullivanlaw.com This Client Alert is provided for general informational purposes only and does not constitute legal advice.

News

All News

Sullivan & Worcester Advances Japan-Focused Capital Markets Initiative, Building on Track Record Connecting International Companies with U.S. Markets

(Originally distributed via Access Newswire on September 3, 2026.) New York, NY – Sullivan & Worcester is expanding its international capital markets platform with a focused initiative to help Japanese companies evaluate and pursue opportunities to access U.S. investors and capital markets. As part of that initiative the firm will serve as a Gold Sponsor of the Japan Go IPO Summit, taking place on September 16, 2026, in Tokyo. Hosted by MarcumAsia and organized by AUM Advisors, the Summit will bring together senior executives and board members of innovative Japanese companies seeking growth capital and opportunities to expand their brands globally. This is the firm’s second year as a sponsor and participant in the Summit. Sullivan’s continued Japan initiative builds on its longstanding experience advising companies from international markets on U.S. capital markets strategies. The firm’s work with Israeli companies provides a particularly strong and successful example of this work. More than two decades ago, Sullivan identified the potential of Israel’s entrepreneurial culture, government support for innovation and strong private-capital ecosystem provided a foundation for companies seeking to grow through the U.S. markets. That strategy has delivered significant results: today, roughly 20 years after beginning that effort, Sullivan represents 22% of Israeli companies traded on Nasdaq. This underscores the firm’s ability to develop deep, long-term relationships with companies in key international markets that are interested in pursuing U.S. capital. Sullivan sees a similarly compelling opportunity in Japan. The country’s technological and manufacturing excellence, public- and private-sector investment across a range of industries, institutional stability and longstanding economic ties with the U.S. create strong conditions for greater cross-border investment and capital-markets activity. “Japan is home to sophisticated companies with strong fundamentals, differentiated technologies and significant global potential,” said David E. Danovitch, Partner at Sullivan and Director of the firm’s Corporate Department. “The U.S. market is increasingly looking for durable, high-quality growth opportunities, and Japan is well positioned to provide them. Our cross-border capital markets experience gives us valuable perspective to help Japanese companies approach the U.S. market with a clear strategy and execute on their long-term objectives.” At the Japan Go IPO Summit, Danovitch will moderate a discussion among leading global investment funds on how they view the investment landscape in Japan, the factors driving investment decisions, and how Japanese companies can position themselves for global growth. The conference will provide Sullivan an opportunity to engage directly with Japanese companies and investors and explore practical considerations surrounding U.S. IPOs, capital raising, public-company readiness and cross-border expansion. The firm’s work in Japan forms part of a broader ASEAN strategy focused on developing long-term relationships with companies and local market participants and connecting them with experienced U.S. legal advisory and financial resources. About Sullivan Sullivan & Worcester (Sullivan) is a premier, AmLaw 200 international law firm with lawyers in Boston, London, New York, Tel Aviv and Washington, D.C. Sullivan’s clients, including Fortune 500 companies, leading financial services firms and asset managers, boards of directors, real estate companies, and emerging businesses, rely on Sullivan’s ability to navigate complex legal and operational landscapes, the impeccable judgment of its lawyers, and its commitment to best-in-class client service.

Sullivan Advises DataVault AI, Inc. on Acquisition of NYIAX, Inc.

Sullivan & Worcester represented Datavault AI Inc. (Nasdaq: DVLT), an Artificial Intelligence Platform company focused on data monetization, tokenization and digital asset technologies, in its acquisition of NYIAX, Inc., a pioneer in blockchain-enabled exchange technology and contract management infrastructure. The acquisition adds NYIAX's institutional-grade exchange technology, blockchain settlement infrastructure and portfolio of intellectual property assets to Datavault AI's platform, strengthening the company's capabilities across the digital asset and real-world asset tokenization lifecycle. The transaction is expected to support Datavault AI's efforts to provide an integrated platform spanning asset origination, valuation, tokenization, commercialization and exchange-based market participation. The Sullivan deal team included Joseph Segilia, David Danovitch, Joonas Aho and Shannon Marini. For more information, please view the full press release here.

Capital Markets

U.S. and foreign businesses rely on Sullivan's Capital Markets group to handle sophisticated financial transactions worldwide. Clients seek our experienced counsel, practical business acumen, international finance connections, and ability to balance legal and business risks.

Initial public offerings (IPOs)
Follow-on/secondary public offerings
Venture capital investments
Private placements of securities
Convertible/equity-linked offerings
Strategic partnerships
SPACs and de-SPAC transactions
Digital asset and tokenized securities offerings
Spin-offs
ATM and ELOCs
Public M&A-related listings and compliance

Clients

Fiduciary duties
Executive compensation
Company policies and procedures
Insurance
Whistleblower complaints
Bylaw provisions
Clawback policies
Risk management
Auditor independence
Internal control over financial reporting; and
Other compliance issues

Representative Client Work

Here is a selected sample of recent Capital Markets clients and experience:

Securities

Sales agent counsel in a $6 billion up-sized At-The-Market (ATM) public offering of common stock, and placement agent counsel in a $425 million private placement of common stock, by a global marketing partner to leading sportsbooks and online casino gaming operators
Issuers or underwriters in numerous IPOs in the biotechnology and technology industries
Office, government properties, senior living and hotel REITs in raising tens of billions of dollars in public and 144A offerings of common equity, straight and convertible preferred equity and senior and convertible debt
Ongoing disclosure, governance and listing advice to Iron Mountain Incorporated, including public and 144A equity and debt offerings
Represented FINRA placement agent in registered direct for a Chinese biotechnology company focusing on early cancer screening and detection
Represented REIT as issuer in first initial public offering (IPO)
Facilitated senior subordinated debt placements denominated in British Pounds Sterling (GPB), Canadian dollars (CAD) and Euro (EUR) for a U.S. public company; provided ongoing disclosure, corporate governance and stock exchange listing advice for same public client
Public senior living community operator in a convertible note offering
Lead underwriter in several follow-on public equity offerings by a biotech company
Public companies acquisitions with both registered and unregistered stock consideration
Various companies in self-tender offers for outstanding notes
A private financial services firm in a $700 million 144A debt offering
A foreign software company in an acquisition and a going private transaction involving U.S. software company
A REIT in an acquisition and public spinoff of a travel center company
A biotech company in multiple "registered direct" offerings of common stock and warrants
A medical devices company traded on the Tel Aviv Stock Exchange in its ADR listing on Nasdaq followed by a $47 million public offering
Software and technology companies in equity and convertible note PIPEs
A financial services company in switching its listing from Nasdaq to NYSE
Companies whose shares were quoted on the OTC markets with uplisting to Nasdaq

Corporate Governance

Ensured observance of Sarbanes-Oxley Act requirements and stock exchange listing standards
Advised on financing alternatives under the JOBS Act
Developed compliance charters, policies and procedures for issuer's board of directors/management
Counseled board committees and independent directors
Offered guidance on procedures for and responses to whistleblower allegations
Advised on adoption of executive compensation "clawback" policy
Facilitated development and oversight of executive compensation plans
Developed disclosure and social media policies
Counseled officers and directors on fiduciary duties and state law governance practices

Capital Markets

U.S. and foreign businesses rely on Sullivan's Capital Markets group to handle sophisticated financial transactions worldwide. Clients seek our experienced counsel, practical business acumen, international finance connections, and ability to balance legal and business risks.

Clients

Representative Client Work

Capital Markets

Capital Markets

Biotech Focused On Developing Non-Opioid Therapeutics to Alleviate Pain Announced IPO

Neural Input Technology Company, Wearable Devices Ltd. IPO

Capital Markets

SEC Approves NYSE and NYSE American $0.25 Minimum Trading Price as Continued Listing Requirement

SEC Stays Approval of Nasdaq’s $5 Million MVLS Continued Listing Requirement Pending Commission Review

SEC Approves Nasdaq's New $5 Million Market Capitalization Threshold for Continued Listing

Sullivan & Worcester Submits Supplemental Comment Letter to SEC on Nasdaq’s Proposed Market Value Listing Requirement

SEC Establishes Retail Fraud Working Group to Combat Fraud Targeting Everyday Investors

Sullivan & Worcester Submits Rebuttal Comment Letter to SEC on Nasdaq’s Proposed Market Value Listing Requirement

SEC Proposes Significant Changes to Public Company Reporting Rules, Including New Filer Categories and Expanded Disclosure Relief

SEC Proposes Reforms to Registered Offering Framework

Sullivan & Worcester Submits Supplemental Comment Letter to SEC on Nasdaq’s Proposed Market Value Listing Requirement

SEC Proposes Optional Semiannual Interim Reporting Framework

Nasdaq Considers a New $5 Million Market Value Threshold for Continued Listing: What Issuers Need to Know

Sullivan & Worcester Submits Comment Letter to SEC on Nasdaq’s Proposed Market Value Listing Requirement

Foreign Private Issuers’ Directors and Officers to Be Subject to Section 16 Reporting

SGX-Nasdaq Dual Listing Framework - Opening New Doors for East Asian Companies

FINRA’s Small-Cap Sweep: Strategic Steps for Broker-Dealers

FINRA Launches Targeted Review of Small-Cap Foreign Offerings

Sullivan & Worcester Submits Comment to SEC on Foreign Private Issuer Definition

SEC Expands Confidential Submission Options for Issuers to Facilitate Capital Raising

New SEC Guidance May Lead to More 5% Shareholders Having to File Schedule 13Ds

SEC Approves NYSE and NYSE American Rule Changes Regarding Minimum Price Criteria Compliance Periods and the Use of Reverse Stock Splits

Nasdaq Changes Rules Regarding Minimum Bid Price Compliance Periods and Restricts the Use of Reverse Stock Splits

How I Made Partner: 'Focus on Being Excellent, Taking Responsibility and Ownership of Matters,' Says Meghan Rohan of Sullivan & Worcester

SEC and CFTC Continue Their Lucrative Pursuits of Penalizing Unapproved Communication Methods

Distressed Debt Investors Beware of Disqualified Lender Lists

SEC Amends Deadlines and Other Rules for Reporting Beneficial Ownership on Schedules 13D and 13G

SEC Adopts Rules for Cybersecurity Disclosures

SEC Adopts Amendments to Share Repurchase Disclosure

The SEC’s Stacked Deck Is News to Unsuspecting 'Dealers'

SEC Adopts Amendments to Modernize Rule 10b5-1 Insider Trading Plans and Related Disclosures

SEC Adopts Rules Requiring Compensation Clawback Policies

Capital Markets

Sullivan & Worcester Advances Japan-Focused Capital Markets Initiative, Building on Track Record Connecting International Companies with U.S. Markets

Sullivan Advises DataVault AI, Inc. on Acquisition of NYIAX, Inc.

Sullivan Advises Lake Street Capital Markets as Underwriter on $25 Million NeoVolta Public Offering

Sullivan Advises Somatix in Merger with Vitalist

SEC Turns the Spotlight On Nasdaq Delisting Standards

Sullivan & Worcester Announces Six Partner Elevations in Boston and New York

Atkins Calls for Leaner Corporate Risk Disclosures, Says Filings Have Become Litigation Shields

Sullivan's Capital Markets Team Recognized by IFLR1000 Middle East

Sullivan & Worcester Attorneys Named to 2025 Top Lawyers List by Boston Magazine

SEC, FINRA Cross-Border Crackdown Typifies Trump 2.0 Priorities

Sullivan Attorneys Selected to 2025 Massachusetts Super Lawyers and Rising Stars Lists

Sullivan & Worcester Announces Creation of Small-Firm Task Force to Address Latest FINRA Small-Cap IPO Sweep

Sullivan & Worcester Associate Chinyere S. Okogeri Selected for 2025 ACG Boston Accelerator Program

Many Foreign Firms Could Face Stricter Access To US Markets

Sullivan & Worcester Hires Fried Frank REIT Tax Pro

Sullivan Expands REIT and Tax Practices with New Partner in D.C.

Irish Firms 'Very Attractive to Investors' – Leading Law Firm Highlights Benefits of US Capital Markets

Sullivan & Worcester Attorneys Named to 2024 Top Lawyers List by Boston Magazine

Sullivan Attorneys Named 2024 Massachusetts Super Lawyers and Rising Stars

Sullivan Ranks High in PlacementTracker's Q2 2024 PIPE and Private Placement Markets League Tables

Brian Hurley Accepted Into the Association for Corporate Growth (ACG) Accelerator Program

Angela Gomes Selected as a 2024 Honoree for the Women's Bar Association's Pioneering Women of Color Celebration

SEC Has Careful Eye On Disclosures Amid Israel-Hamas War

Sullivan, One of the Top 200 Law Firms in the US, Wants to Help Irish Companies Raise Capital in America

Sullivan Attorneys Named to 2023 Top Lawyers List by Boston Magazine

Sullivan & Worcester Ranked by Best Law Firms® in 2024

Sullivan Attorneys Named 2023 Massachusetts Super Lawyers and Rising Stars

Israeli Future of Fem-Tech Healthcare Event

Rule Hastening Disclosure of Cyber Breaches Likely to Ignite Litigation, Insurance Headaches

43 Sullivan & Worcester Attorneys Listed in Best Lawyers in America® 2024 Edition

Capital Markets

U.S. and foreign businesses rely on Sullivan's Capital Markets group to handle sophisticated financial transactions worldwide. Clients seek our experienced counsel, practical business acumen, international finance connections, and ability to balance legal and business risks.

Clients

Representative Client Work

Capital Markets

U.S. and foreign businesses rely on Sullivan's Capital Markets group to handle sophisticated financial transactions worldwide. Clients seek our experienced counsel, practical business acumen, international finance connections, and ability to balance legal and business risks.

Clients

Representative Client Work

Capital Markets

SEC Adopts Pay Versus Performance Disclosure Rules